Most cited papers in Cholinesterase and Neurodegenerative Diseases
What are the most cited papers in Cholinesterase and Neurodegenerative Diseases?
The most cited paper in Cholinesterase and Neurodegenerative Diseases is "A new and rapid colorimetric determination of acetylcholinesterase activity" (George L. Ellman, K. Diane Courtney, Valentino Andres et al., 1961), with 27,264 citations. Next come "The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics" (14,017) and "Superoxide dismutase: Improved assays and an assay applicable to acrylamide gels" (12,959).
Showing 50 of 99 papers. Every paper with more than 1,253 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | A new and rapid colorimetric determination of acetylcholinesterase activity George L. Ellman, K. Diane Courtney, Valentino Andres et al. · Biochemical Pharmacology | Jul 1961 | 27,264 |
| 2 | The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics John Hardy, Dennis J. Selkoe · Science | 19 Jul 2002 | 14,017 |
| 3 | Superoxide dismutase: Improved assays and an assay applicable to acrylamide gels Charles Beauchamp, Irwin Fridovich · Analytical Biochemistry | Nov 1971 | 12,959 |
| 4 | Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families Elizabeth H. Corder, Ann M. Saunders, Warren J. Strittmatter et al. · Science | 13 Aug 1993 | 9,582 |
| 5 | Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity Elisabetta Polazzi, Ilaria Mengoni, Marco Caprini et al. · Neurosignals | 9 May 2012 | 9,018 |
| 6 | Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Reisa Anne Sperling et al. · Alzheimer s & Dementia | 22 Apr 2011 | 7,286 |
| 7 | International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels William A. Catterall, K. George Chandy, David E. Clapham et al. · Pharmacological Reviews | Dec 2003 | 7,147 |
| 8 | Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis Daniel R. Rosen et al. · Nature | Mar 1993 | 7,116 |
| 9 | Alzheimer's Disease: Genes, Proteins, and Therapy Dennis J. Selkoe · Physiological Reviews | Apr 2001 | 6,113 |
| 10 | The Cholinergic Hypothesis of Geriatric Memory Dysfunction Raymond T. Bartus, Reginald L. Dean, Bernard Beer et al. · Science | 30 Jul 1982 | 5,576 |
| 11 | Alzheimer's Disease Henry W. Querfurth, Frank M. LaFerla · New England Journal of Medicine | 27 Jan 2010 | 4,526 |
| 12 | Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo Dominic M. Walsh, Igor V. Klyubin, Julia V. Fadeeva et al. · Nature | Apr 2002 | 4,323 |
| 13 | β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE Robert J. Vassar et al. · Science | 22 Oct 1999 | 3,870 |
| 14 | Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain PJ Whitehouse, DL Price, R. G. Struble et al. · Science | 5 Mar 1982 | 3,640 |
| 15 | Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy Chia‐Chen Liu, Takahisa Kanekiyo, Huaxi Xu et al. · Nature Reviews Neurology | 8 Jan 2013 | 3,567 |
| 16 | Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins Mary P. Lambert, Avlin K. Barlow, Brett A. Chromy et al. · Proceedings of the National Academy of Sciences | 26 May 1998 | 3,539 |
| 17 | Alzheimer Disease: An Update on Pathobiology and Treatment Strategies Justin M. Long, David M. Holtzman · Cell | 26 Sep 2019 | 3,342 |
| 18 | ProTox-II: a webserver for the prediction of toxicity of chemicals Priyanka Banerjee, Andreas Philipp Eckert, Anna K. Schrey et al. · Nucleic Acids Research | 26 Apr 2018 | 3,237 |
| 19 | Carbonic anhydrases: novel therapeutic applications for inhibitors and activators Claudiu Trandafir Supuran · Nature Reviews Drug Discovery | 2 Jan 2008 | 3,205 |
| 20 | The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease Jeff Sevigny et al. · Nature | 30 Aug 2016 | 3,131 |
| 21 | Alzheimer's disease Kaj Blennow, Mony J. de Leon, Henrik Zetterberg · The Lancet | Jul 2006 | 3,113 |
| 22 | Pathways towards and away from Alzheimer's disease Mark P. Mattson · Nature | 4 Aug 2004 | 3,075 |
| 23 | Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation Joseph T. Coyle, Donald L. Price, Mahlon R. DeLong · Science | 11 Mar 1983 | 3,071 |
| 24 | Comprehensive Review on Alzheimer’s Disease: Causes and Treatment Zeinab Breijyeh, Rafik Karaman · Molecules | 8 Dec 2020 | 2,780 |
| 25 | The molecular pathology of Alzheimer's disease Dennis J. Selkoe · Neuron | Apr 1991 | 2,750 |
| 26 | Atomic Structure of Acetylcholinesterase from Torpedo californica : A Prototypic Acetylcholine-Binding Protein Joel L. Sussman, Michal Harel, Felix Frolow et al. · Science | 23 Aug 1991 | 2,723 |
| 27 | Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung David W. Cushman, Hong Son Cheung · Biochemical Pharmacology | Jul 1971 | 2,638 |
| 28 | Acetylcholinesterase Inhibitors: Pharmacology and Toxicology Mirjana B. Čolović, Danijela Z. Krstic, Tamara D. Lazarević Pašti et al. · Current Neuropharmacology | Apr 2013 | 2,613 |
| 29 | Alzheimer's disease Chris Lane, John Hardy, Jonathan M. Schott · European Journal of Neurology | 5 Sep 2017 | 2,612 |
| 30 | Alzheimer disease David S. Knopman, Hélène Amieva, Ronald Carl Petersen et al. · Nature Reviews Disease Primers | 13 May 2021 | 2,543 |
| 31 | Pathological roles of MAPK signaling pathways in human diseases Eun-Kyung Kim, Eui‐Ju Choi · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease | 15 Jan 2010 | 2,527 |
| 32 | Oxidative Stress Hypothesis in Alzheimer's Disease William R. Markesbery · Free Radical Biology and Medicine | 1997 | 2,390 |
| 33 | Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1–Ch6) M.‐Marsel Mesulam, Elliott Jay Mufson, Bruce H. Wainer et al. · Neuroscience | Dec 1983 | 2,341 |
| 34 | Alzheimer's Disease: Cell-Specific Pathology Isolates the Hippocampal Formation Bradley T. Hyman, Gary W. Van Hoesen, António R. Damásio et al. · Science | 14 Sep 1984 | 2,286 |
| 35 | admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties Feixiong Cheng, Weihua Li, Yadi Zhou et al. · Journal of Chemical Information and Modeling | 23 Oct 2012 | 2,269 |
| 36 | The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics Eric H. Karran, Marc H. Mercken, Bart De Strooper · Nature Reviews Drug Discovery | 19 Aug 2011 | 2,240 |
| 37 | Amyloid-β and Tau George S. Bloom · JAMA Neurology | 3 Feb 2014 | 2,235 |
| 38 | Tau-mediated neurodegeneration in Alzheimer's disease and related disorders Carlo Ballatore, Virginia M.‐Y. Lee, John Q. Trojanowski · Nature reviews. Neuroscience | 8 Aug 2007 | 2,217 |
| 39 | Oxidative stress and the amyloid beta peptide in Alzheimer’s disease Clémence Cheignon, Mireia Tomas, Dominique Bonnefont‐Rousselot et al. · Redox Biology | 19 Oct 2017 | 2,206 |
| 40 | The cholinergic hypothesis of Alzheimer's disease: a review of progress Paul T. Francis, Alan M. Palmer, Mike Snape et al. · Journal of Neurology Neurosurgery & Psychiatry | Feb 1999 | 2,197 |
| 41 | Amyloid Precursor Protein Processing and Alzheimer's Disease Richard O’Brien, Philip C. Wong · Annual Review of Neuroscience | Mar 2011 | 2,108 |
| 42 | Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene Evgeny Ivanovich Rogaev et al. · Nature | Aug 1995 | 2,073 |
| 43 | Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Elaine K. Perry, B. E. Tomlinson, G. Blessed et al. · BMJ | 25 Nov 1978 | 2,055 |
| 44 | Amyloid beta: structure, biology and structure-based therapeutic development Guo-fang Chen, Ting-Hai Xu, Yan Yan et al. · Acta Pharmacologica Sinica | 17 Jul 2017 | 2,015 |
| 45 | The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes Iryna Benilova, Eric H. Karran, Bart De Strooper · Nature Neuroscience | 29 Jan 2012 | 2,009 |
| 46 | Intracellular amyloid-β in Alzheimer's disease Frank M. LaFerla, Kim N. Green, Salvatore Oddo · Nature reviews. Neuroscience | 6 Jun 2007 | 1,959 |
| 47 | Aβ Oligomers – a decade of discovery Dominic M. Walsh, Dennis J. Selkoe · Journal of Neurochemistry | 4 Jan 2007 | 1,947 |
| 48 | Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease Elizabeth H. Corder, Ann M. Saunders, NEIL J. RISCH et al. · Nature Genetics | Jun 1994 | 1,941 |
| 49 | The Amyloid-β Pathway in Alzheimer’s Disease Harald Juergen Hampel, John Hardy, Kaj Blennow et al. · Molecular Psychiatry | 29 Aug 2021 | 1,929 |
| 50 | Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model Erik D. Roberson, Kimberly A. Scearce-Levie, Jorge J. Palop et al. · Science | 3 May 2007 | 1,918 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.